Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL1RAP-targeting CAR-T Cells in Relapsed/Refractory Hepatocellular Carcinoma
NCT06757881Phase 1Active, not recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jan 2025
- Primary completion
- Aug 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-IL1RAP CAR-T cells in hepatocellular carcinoma (HCC), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Dose Limiting Toxicity at 28 days, Adverse Events and Serious Adverse Events at 12 months and 2 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
anti-IL1RAP CAR-T cells
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06757881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757881.